This group began by looking at previous and current major clinical trials of hydroxyurea (HU) therapy in sickle cell disease (SCD).
In sub-Saharan Africa there is infrequent use of HU therapy although certain medical centres in Africa have considerable interest in conducting formal studies.
The group also addresses barriers to HU therapy including;
Patients in developing countries need to be enrolled in clinical research however there is uncertainty about the impact of infections and differences in local environment of HU efficacy, risks, and outcomes.
SCD must be recognized as a public health priority in order to pursue adequate funding for SCD related health care including infrastructure support for HU therapy.